ArticleJournal of Cancer2025
Pan-cancer analyses reveal cancer-type-specific autophagy signatures with potential implications for prognosis and therapy response.
Article in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrating single-cell and spatial transcriptomics with pan-cancer bulk sequencing identifies OSR2 as a multifaceted biomarker for prognosis and tumor immunity.Discover oncology · 2026Article
- Crosstalk between NRP1 and autophagy in the tumor microenvironment: from molecular mechanisms to therapeutic targeting.Frontiers in immunology · 2026Review
- SQSTM1/p62 as a prognostic indicator in pancancer and nasopharyngeal carcinoma.BMC research notes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy is a common cellular degradation and recycling process that plays crucial roles in the development, progression, immune regulation, and prognosis of various cancers. However, a systematic assessment of the autophagy-related genes (ATGs) across cancer types is deficient. Here, a transcriptome-based pan-cancer analysis of autophagy with potential implications in prognosis and therapy response was performed. About 3 - 32 % of ATGs expressed differentially across 21 human cancers, and the autophagy-related score (ATS) based on differential ATGs could be used to predict the prognosis in 11 cancers, which was validated in multiple independent datasets. Autophagy was found to influence tumor immune microenvironment mainly by regulating tumor-infiltrating lymphocytes and myeloid-derived cells, and interactions between T cells and macrophages with lower ATS was enhanced to improve clinical outcomes by single cell analysis in bladder urothelial carcinoma (BLCA). In addition, the ATS was correlated with drug sensitivity and showed a capacity for prediction of therapy response in diverse cancers. Altogether, the results highlighted robust value of autophagy in cancer prognosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.